Overview

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Status:
Recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the Pyrotinib in combination with albumin-bound paclitaxel and trastuzumab to neoadjuvant therapy efficacy and safety of Her2-positive early or locally advanced breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

West China Hospital

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Trastuzumab